INTRODUCTION {#s1}
============

Subependymal giant cell astrocytomas (SEGAs) are rare, low-grade brain tumors that generally develop during the first two decades of life in 10-20% of patients with tuberous sclerosis complex (TSC) \[[@R1]--[@R3]\]. TSC is an autosomal dominant neurocutaneous disorder caused by mutations in either *TSC1* encoding hamartin, or *TSC2* encoding tuberin. Together these two proteins form the TSC protein complex that regulates mechanistic target of rapamycin complex 1 (mTORC1) \[[@R4]--[@R6]\]. In the central nervous system, TSC is characterized by the development of SEGAs, subependymal nodules (SEN), cortical tubers and cortical migration tracts \[[@R7]\]. SEGAs represent 1%-2% of all pediatric brain tumors and usually arise near the foramen of Monro \[[@R8]--[@R10]\]. They are a potential cause of major morbidity and mortality in TSC \[[@R11]\]. Extended growth of the tumor can cause obstruction of cerebrospinal fluid tract resulting in hydrocephalus and increased intracranial pressure with subsequent death if neglected. SEGAs are treated with either surgical resection or mTORC1 inhibitors including everolimus.

Histopathologically, SEGAs consist of spindle cells, gemistocytic-like cells and giant cells. According to the present world health organization (WHO) classification of brain tumors, SEGAs belong to the group of astrocytic neoplasms, even though they have both glial and neuronal expression patterns \[[@R12], [@R13]\]. SEGAs likely develop from SEN, but the molecular mechanisms underlying their progressive growth, in contrast to SEN, are unknown so far \[[@R14], [@R15]\]. There is evidence of second-hit inactivation of *TSC1* or *TSC2* in SEGAs, suggesting that one contributor to SEGA development is the complete loss of a functional tuberin-hamartin complex and the subsequent mTORC1 activation \[[@R16]--[@R18]\]. However, it is likely that second-hit mutations in *TSC1* and *TSC2* also contribute to SEN formation, suggesting that additional genetic events may contribute to the progressive growth of SEGAs.

BRAF is a kinase that activates the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway which regulates cell proliferation, survival and cell-cycle arrest \[[@R19]\]. The *BRAF* c.1799T\>A (p.V600E) mutation (*BRAF^V600E^*) results in constitutive activation of MAPK/ERK signaling and is well known in both pediatric and adult low-grade gliomas, including pilocytic astrocytoma (PA), pleomorphic xanthoastrocytoma (PXA), ganglioglioma (GG), desmoplastic infantile gangliogliomas (DIG), and dysembyoplastic neuroepithelial tumor (DNET) \[[@R20]--[@R26]\]. Although the prevalence of *BRAF* mutations in low grade gliomas is relatively low \[[@R22]\], *BRAF^V600E^* mutations have been consistently reported as genetic driver in gangliogliomas (18-56%), and have been associated with mTORC1 activation \[[@R20], [@R25]\].

Both protein kinase B (AKT) and MAPK/ERK pathways have been reported to be activated in SEGAs \[[@R27]--[@R31]\]. However, the genetic basis for MAPK/ERK and AKT activation in SEGAs is unknown. The *BRAF^V600E^* mutation was reported in a small set (6 of 14 cases) of SEGAs \[[@R23]\] suggesting that it could explain MAPK/ERK and AKT activation in SEGAs. However, subsequent studies have produced contradictory results, failing to confirm the presence of the *BRAF^V600E^* mutation in SEGAs \[[@R18], [@R21], [@R23], [@R26], [@R32]\].

In the present study, we examined the possibility that *BRAF* mutations occur in SEGA using a large international cohort of fifty-eight SEGAs from both pediatric and adult TSC patients.

RESULTS {#s2}
=======

Samples and clinical features {#s2_1}
-----------------------------

Fifty-eight SEGAs and one SEN from 58 patients were analyzed (62% male, 36% female; Table [1](#T1){ref-type="table"}). Fifty-six patients had a definite clinical diagnosis of TSC, whereas two patients did not show other signs of TSC apart from the tumor. *TSC1*/*TSC2* mutation analysis was performed as part of routine clinical care on blood or tumor DNA for 19 subjects, such that 7 had *TSC1* and 12 had *TSC2* mutations. For 34 samples we performed *TSC1/TSC2* mutation analysis using massively parallel sequencing (MPS); for the remaining 5 samples there was insufficient DNA for this analysis.

###### Summary of clinicopathological features in TSC patients with subependymal giant cell astrocytoma

  Parameter                    Number   \%
  ---------------------------- -------- ----
  Age                                   
   ≤18                         37       64
   \>18                        21       36
  Sex                                   
   Male                        36       62
   Female                      22       37
  Tumor location                        
   Lateral ventricle           49       84
   Foramen of Monro            5        9
   Third ventricle             4        7
  TSC-lesions                           
   SEN/Tubers                  56       96
  Tuberous Sclerosis Complex            
   Definite                    56       97
   Possible                    2        3

Ages ranged from 1 to 53 years at the time of surgery. The large majority of patients had a lesion located in the lateral ventricle near the foramen of Monro and five patients had bilateral tumors. Histological diagnosis was confirmed following the current WHO classification guidelines by two independent neuropathologists \[[@R33]\]. All cases had classical histological features of SEGA, showing mainly giant cells with eosinophilic cytoplasm (Figure [1A](#F1){ref-type="fig"}). Smaller gemistocytic cells, fibrillary astrocytes and a variable number of multinucleated cells were also noted in all cases. Calcifications were observed in 13/44 FFPE cases (30%). As previously reported \[[@R13], [@R34]--[@R36]\], immunohistochemical analysis revealed variable expression of glial and neuronal markers (Figures [1B-1C](#F1){ref-type="fig"}). We also observed prominent presence of microglial cells intratumoral T-lymphocytes (Figures [1D-1E](#F1){ref-type="fig"}) and evidence of activation of mTORC1 pathway with phospho-S6 ribosomal protein immunoreactivity (Figure [1F](#F1){ref-type="fig"}). The differential diagnosis of SEGA takes into account other tumors arising in the region of the basal ganglia and in the lateral and third ventricles (diffuse astrocytoma, ependymoma, central neurocytoma, choroid plexus papilloma). SEGA outside the setting of TSC are rare \[[@R37], [@R38]\], as well as SEGA within cortical tubers \[[@R39]\]. In our cohort, nearly all patients (n=56) had other central nervous system TSC-associated lesions (SEN and cortical tubers) associated with refractory epilepsy, making the diagnosis reasonably certain before resection.

![Subependymal giant cell astrocytomas (SEGAs)\
**(A)** Hematoxylin and eosin staining of a SEGA tumor presenting classical histological features, with giant cells (large cells with abundant eosinophilic cytoplasm and nuclei with prominent nucleoli; high magnification in insert) in a mixed glial background and blood vessels. **(B)** GFAP showing areas of diffuse immunoreactivity. **(C)** Variable expression of neuronal markers, including MAP2 is observed within the tumor (arrow shows MAP2 expression in a giant cell). **(D)** HLA-DR shows prominent presence of microglial cells. **(E)** CD3 staining shows intratumoral T lymphocytes (arrows). **(F)** pS6 shows several positive tumor cells. Scale bars: 80 μm.](oncotarget-08-95516-g001){#F1}

BRAF mutational analysis {#s2_2}
------------------------

Sanger sequencing analysis for the *BRAF^V600E^* mutation in all 58 SEGA samples tested and the SEN was negative (Figure [2](#F2){ref-type="fig"}). Furthermore, no other variants were found in exon 15 of *BRAF* in any sample. We also performed RT-PCR to screen for five different types of gene fusions between *KIAA1549* and *BRAF* on 6 SEGAs from which RNA was available (Table [2](#T2){ref-type="table"}; data not shown). There was no evidence for the presence of *KIAA1549-BRAF* fusions in the six SEGA cases analyzed. *BRAF* mutational analysis was also performed by MPS for all SEGA samples for which there was sufficient DNA to permit this method of analysis, n=31 (Table [3B](#T3B){ref-type="table"}). None of the samples showed the *BRAF^V600E^* mutation, even at an allele frequency of 5-10%. Five intronic variants were identified, all known single nucleotide polymorphisms (SNPs; data not shown). Two coding variants in exon 1 were identified, c.82G\>T (p.G28C) at allele frequency 100% in one sample, and c.31G\>Ap (p.G11S) at allele frequency 56% in a second sample (Table [3B](#T3B){ref-type="table"}). These are not known germline variants (per Exac). The p.G11S variant has been reported in a single hepatocellular carcinoma, while the p.G28C variant has not been seen previously in cancer (per cBio). Furthermore, these two variants showed no evidence of pathogenicity based on three different in silico prediction tools.

![Direct sequencing of exon 15 of *BRAF* for detection of the V600E mutation\
**(A)** Schematic overview showing the forward and reverse sequence of *BRAF* exon 15 at codon 598 through codon 602 for both wild-type and the c.1799T\>A (p.V600E) mutation. **(B)** Positive control. Pilocytic astrocytoma with the *BRAF^V600E^* mutation shows c.1799T\>A in the forward sequence (left) and reverse sequence (right), resulting in the p.V600E amino acid substitution (arrow). **(C)** SEGA showing the wild-type GTG forward sequence (left) and CAC reverse sequence (right). **(D)** SEN with the V600 codon showing the wild-type GTG forward sequence (left) and CAC reverse sequence (right). Arrows indicate codon 600 of *BRAF*.](oncotarget-08-95516-g002){#F2}

###### Primer sequences for detection of *KIAA1549:BRAF* fusion genes

  Gene                     Exon variant (*KIAA1549:BRAF*)   Forward Primer (5'-\>3')   Reverse primer (5'-\>3')
  ------------------------ -------------------------------- -------------------------- --------------------------
  *KIAA1549-BRAF* fusion   Ex16:Ex9                         CTACAGCCCAGCCCAGAC         GTGAGCCAGGTAATGAGGCAG
  *KIAA1549-BRAF* fusion   Ex15:Ex9                         CCACAACTCAGCCTACATCGG      GTGAGCCAGGTAATGAGGCAG
  *KIAA1549-BRAF* fusion   Ex16:Ex11                        AGACGGCCAACAATCCCTGC       GTCCCACTGTAATCTGCCC
  *KIAA1549-BRAF* fusion   Ex18:Ex10                        GAGGGATCTACTCGGAGGAG       GTGAGCCAGGTAATGAGGCAG
  *KIAA1549-BRAF* fusion   Ex19:Ex9                         GAAGCGGGGCGAAGAGAG         GTGAGCCAGGTAATGAGGCAG
  *PBGD*                   \-                               CTGGTAACGGCAATGCGGCT       GCAGATGGCTCCGATGGTGA
  *B2M*                    \-                               AGCATTCAGACTTGTTTCAG       GATGCTGCTTAGATGTCTCG

###### Summary of results for *TSC1/TSC2* mutational analysis in 34 SEGA samples by MPS. NMI = No Mutation Identified, MAF = mutant allele frequency, CN-LOH = Copy neutral loss of heterozygosity, point = point mutation or small insertion or deletion

  Case (\#)   Gene     Nucleotide change                  MAF (%)   Mutation type        Protein change           CN-LOH   Summary
  ----------- -------- ---------------------------------- --------- -------------------- ------------------------ -------- -----------------------------------------------------
  1           NMI                                                                                                          
  2           NMI      *TSC1* c.1-7G\>A                   50        Possible initiator                            No       Possible *TSC1* mutation, no CN-LOH
  3           *TSC1*   chr9:135700060-135799506del        78        Genomic deletion     deletion of exons 6-23   Yes      large del+ CN-LOH
  4           *TSC1*   c.1498C\>T                         71        Nonsense             p.R500^\*^               Yes      point+CN-LOH
  5           *TSC1*   c.641_644dupAGAC                   93        Insertion            p.F216Dfs^\*^3           Yes      point+CN-LOH
  6           *TSC1*   c.2074C\>T                         39        Nonsense             p.R692^\*^               Yes      point+CN-LOH
  7           *TSC1*   c.1525C\>T                         12        Nonsense             p.R509^\*^               No       Point-no LOH
  8           *TSC1*   c.2699dupA                         65        Insertion            p.Q901Efs^\*^3           Yes      point+CN-LOH
  9           *TSC1*   c.1802dupC                         79        Insertion            p.P602Sfs^\*^4           Yes      point+CN-LOH
  10          *TSC1*   c.935dupA                          29        Nonsense             p.Y312^\*^               Yes      point+CN-LOH
  11          *TSC1*   c.1525C\>T                         76        Nonsense             p.R509^\*^               Yes      point+CN-LOH
  12          *TSC1*   c.2695C\>T                         70        Nonsense             p.Q899^\*^               Yes      point+CN-LOH
  13          *TSC2*   c.4375C\>T                         50        Nonsense             p.R1459^\*^              No       point no LOH (sporadic SEGA; no other signs of TSC)
  14          *TSC2*   c.3412C\>T                         68        Nonsense             p.R1138^\*^              Yes      point+CN-LOH
  15          *TSC2*   c.2353C\>T                         12        Nonsense             p.Q785^\*^               Yes      point+CN-LOH
  16          *TSC2*   c.2221-1G\>C                       55        Splice               p.L741_splice            Yes      point+CN-LOH
  17          *TSC2*   c.790_791delCT                     30        Deletion             p.L264Wfs^\*^73          No       Point, no LOH
  18          *TSC2*   c.903_922delGGCTCTCTGGGGAGCCCACC   34        Deletion             p.W304Ffs^\*^27          Yes      point+CN-LOH
  19          *TSC2*   c.5227_5244delCGGCTCCGCCACATCAAG   72        In-frame deletion    p.R1743_K1748del         Yes      point+CN-LOH
  20          *TSC2*   c.1832G\>A                         65        Missense             p.R611Q                  Yes      point+CN-LOH
  21          *TSC2*   c.3526_3527insT                    38        Insertion            p.P1176fs                Yes      point+CN-LOH
  22          *TSC2*   c.1513C\>T                         47        Nonsense             p.R505^\*^               Yes      point+CN-LOH
  23          *TSC2*   c.3171_3172insA                    17        Insertion            p.T1059Nfs^\*^109        No       point -no LOH
  24          *TSC2*   c.268C\>T                          75        Nonsense             p.Q90^\*^                Yes      point+CN-LOH
  25          *TSC2*   c.2251C\>T                         63        Nonsense             p.R751^\*^               Yes      point+CN-LOH
  26          *TSC2*   c.5227_5244delCGGCTCCGCCACATCAAG   80        In-frame deletion    p.R1743_K1748del         Yes      point+CN-LOH (sporadic SEGA; no other signs of TSC)
  27          *TSC2*   c.5168C\>A                         34        Nonsense             p.S1723^\*^              Yes      point+CN-LOH
  28          *TSC2*   c.3599G\>C                         57        Missense             p.R1200P                 Yes      point+CN-LOH
  29          *TSC2*   c.1372C\>T                         32        Nonsense             p.R458^\*^               Yes      point+CN-LOH
  30          *TSC2*   c.3814+1G\>C                       47        Splice               p.V1272_splice           No       2 points
                       c.1831C\>T                         15        Missense             p.R611W                           
  31          *TSC2*   c.412G\>T                          51        Nonsense             p.E138^\*^               No       point no LOH
  32          *TSC2*                                                                                              Yes      *TSC2* CN-LOH,no point
  33          *TSC2*                                                                                              Yes      *TSC2* CN-LOH,no point
  34          *TSC2*                                                                                              Yes      *TSC2* CN-LOH,no point

###### Summary of results for *BRAF* mutational analysis by MPS in 31 SEGA samples

  Case (\#)   Gene     Nucleotide change   MAF (%)   Mutation type   Protein change   Summary
  ----------- -------- ------------------- --------- --------------- ---------------- ---------------------------------------------------------------
  25          *BRAF*   c.82G\>T            100       Missense        p.G28C           Novel per cBio,not seen in ExAC
  8           *BRAF*   c.31G\>A            56        Missense        p.G11S           Seen once in an hepatobiliary cancer (cBio), not seen in ExAC

TSC1/TSC2 mutational analysis {#s2_3}
-----------------------------

*TSC1/TSC2* mutational analysis was performed by MPS for 34 SEGA samples (Table [3A](#T3A){ref-type="table"}, Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}). In 19 (56%) samples *TSC2* mutation was identified, 10 (29%) had mutations in *TSC1*, and 5 (15%) had no mutation identified (NMI) in either *TSC1* or *TSC2.* Of the 5 NMI samples 3 showed copy neutral loss of heterozygosity (CN-LOH) for *TSC2* and another sample had a possible *TSC1* mutation. Nine of 10 (89%) samples with a *TSC1* mutation also showed evidence of CN-LOH for *TSC1*, 14 of 19 (74%) samples with a *TSC2* mutation also showed evidence of CN-LOH for *TSC2*, while in 1 sample two small *TSC2* mutations were identified.

![Map of *TSC1* and *TSC2* mutations identified in 10 and 19 SEGA tumors, respectively\
Novel variants (n = 9) are in blue font whereas variants previously reported (n = 16) are in black font. Circle colors present different mutation types, as indicated. **(A)** Map of TSC1 mutations. One *TSC1* mutation (p.R509^\*^) was seen in two different tumor samples; a large genomic deletion (deletion of exons 6-23) and a possible *TSC1* mutation (c.1-7G\>A) are not shown. **(B)** map of TSC2 mutations. Two *TSC2* mutations differ by a single nucleotide position in the same amino acid (p.R611Q/ p.R611W), and hence their circles overlap; one *TSC2* mutation (p.R1743_K1748del) was seen in two different tumor samples.](oncotarget-08-95516-g003){#F3}

![Pie charts demonstrating the *TSC1/TSC2* variant types and mutant allele frequencies in the SEGA tumors analyzed\
**(A)** Percentage of subjects with *TSC1/TSC2* mutations identified vs. NMI. **(B)** Different mutation types in the SEGA cohort studied.](oncotarget-08-95516-g004){#F4}

DISCUSSION {#s3}
==========

SEGAs are low-grade brain tumors associated with TSC and represent 1%-2% of all pediatric brain tumors \[[@R1], [@R10]\]. Due to the scarcity of resected SEGAs, studies to investigate the genetic profile of this tumor type have been restricted to a small number of samples/cases. More specifically, investigation of the presence of a *BRAF^V600E^* mutation in SEGAs has been limited to four individual studies with controversial results \[[@R18], [@R23], [@R26], [@R32]\].

In the present study, we analyzed the largest SEGA cohort to date, consisting of fifty-eight SEGAs. Amongst the cohort the vast majority of cases (97%) were clinically diagnosed as definite TSC meeting the required criteria \[[@R40], [@R41]\]. We did not detect the cancer-actionable *BRAF^V600E^* mutation by direct sequencing or in the MPS analysis in any of the samples tested. Furthermore, there was no evidence for the presence of *KIAA1549-BRAF* fusions in the 6 SEGAs that were analyzed. However, no significant conclusions on *BRAF* fusion mutations in SEGAs could be drawn based on this small sample size (N=6). In the studies that have reported SEGA cases with *BRAF^V600E^* mutations, only two were diagnosed with definite TSC, while the remaining *BRAF^V600E^* positive samples were either TSC negative or defined as possible TSC \[[@R23], [@R26]\]. Altogether, these results suggest that SEGAs derived from patients with TSC, are negative for the *BRAF^V600E^* mutation \[[@R18], [@R21], [@R23], [@R26], [@R32]\].

Additionally, our results indicate that *TSC1*/*TSC2* alterations, including CN-LOH, are nearly universally present in SEGAs, consistent with *TSC1*/*TSC2* molecular findings seen in other TSC-related tumors e.g. renal angiomyolipomas (AMLs) and lymphangioleiomyomatosis (LAM) \[[@R42]\]. *TSC2* LOH has also been reported in sporadic renal and hepatic AMLs as well as sporadic perivascular epithelioid cell tumors \[[@R42],[@R43]\]. Conversely, TSC1 mutation and LOH is rare in angiomyolipoma and perivascular epithelioid cell tumors \[[@R42]--[@R45]\]. In contrast TSC1 mutations and LOH were relatively common in this series, seen in 10 of 34 (29%) and 9 of 34 (26%), respectively. Regarding the 5 SEGA cases in which no definite small mutation was identified, there are several possible causes. First the DNA quality of many SEGA samples was poor, limiting the sensitivity of the MPS analysis. In particular large genomic deletions may have been missed in this analysis, and are relatively common in TSC2 \[[@R42]\].

Consequently, the mechanism of MAPK/ERK and AKT pathway activation in SEGAs \[[@R27]--[@R31]\] is uncertain, and further investigation is required.

MATERIALS AND METHODS {#s4}
=====================

SEGA tumor specimens {#s4_1}
--------------------

SEGA specimens were obtained from the following sites: the Academic Medical Center of Amsterdam, the University Medical Center Utrecht, University Medical Center Groningen, University Hospital Erlangen, University Hospital Münster, Medical University of Vienna, Children\'s Memorial Health Institute in Warsaw, Meyer Children\'s Hospital in Florence, Hacettepe University in Ankara, and the University Hospital de Santa Maria (CHLN) University Hospital de Santa Maria (CHLN) in Lisbon. Fifty-eight SEGAs and one SEN were available from 58 patients of which 56 met standard diagnostic criteria for TSC (Table [1](#T1){ref-type="table"}) \[[@R40], [@R41]\]. Specimens were obtained and used in accordance with the Declaration of Helsinki and this study was approved by the Medical Ethics Committee of each institution.

Histopathological evaluation {#s4_2}
----------------------------

Tissue was fixed in 10% buffered formalin and embedded in paraffin. Paraffin-embedded tissue was sectioned at 6 μm, mounted on organosilane-coated slides (Sigma, St. Louis, MO, USA) and stained with hematoxylin-eosin (HE) for the morphological evaluation. Histological diagnosis was performed according to the 2016 WHO classification of the central nervous system \[[@R33]\]. Sections of the most representative paraffin-embedded specimen of each case were used for additional immunocytochemical staining, as previously reported \[[@R34], [@R35]\]. The following antibodies have been used: glial fibrillary acidic protein (GFAP; polyclonal rabbit, DAKO, Glostrup, Denmark; 1:4000; monoclonal mouse; DAKO; 1:50), microtubule-associated protein (MAP2; mouse clone HM2; Sigma 1:100), anti-human leukocyte antigen (HLA)-DP, DQ, DR (mouse clone CR3/43; DAKO; 1:100), CD3 (mouse monoclonal, clone F7.2.38; DAKO; 1:200; T-lymphocytes), phospho-S6 ribosomal protein (Ser235/236; pS6, rabbit polyclonal, Cell Signaling Technology, Beverly, MA, USA; 1:50) and Ki67 (mouse clone MIB-1, DAKO, Glostrup, Denmark. 1:20) were used in the routine immunocytochemical analysis of tumor specimens to document the presence of a heterogeneous population of cells and the activation of the mTORC1 pathway. After washing in PBS, sections were stained with a polymer based peroxidase immunocytochemistry detection kit (BrightVision Peroxidase system, ImmunoVision, Brisbane, CA, USA). Signal was detected using the chromogen 3-amino-9-ethylcarbazole (AEC, Sigma-Aldrich, St. Louis, MO, USA).

DNA extraction and BRAF^V600E^ mutation analysis {#s4_3}
------------------------------------------------

DNA was extracted from both FFPE (n=44) and frozen (n=14) SEGA tumor samples. Since SEGA often display intratumoral hemorrhages, areas of representative tumor (identified on hematoxylin & eosin stained sections) were selected for cases in which hemorrhages, were observed within the FFPE SEGA tissue samples (n=44). Tumor DNA was extracted from 10-μm-thick paraffin sections using BiOstic FFPE Tissue DNA Isolation kit (MO BIO) according to the manufacturer\'s instructions. From frozen tissue samples (N=14) DNA was recovered from the organic phase following QIAzol (Qiagen) extraction of RNA and was further purified using QIAamp DNA mini Kit (Qiagen). PCR amplification for the entire extent of exon 15 of *BRAF* including codon 600 was performed as previously described using primers TCATAATGCTTGCTCTGATAGGA and GGCCAAAAATTTAATCAGTGGA \[[@R26]\]. Purified PCR products were sequenced by the Sanger method using the Big Dye Terminator Cycle Sequencing Kit (PerkinElmer Biosystems, Foster City, CA, USA).

KIAA1549--BRAF gene fusion {#s4_4}
--------------------------

Six SEGA tissue samples were tested for *KIAA1549*-*BRAF* fusions in a diagnostic setting. Total RNA was extracted from frozen tissue samples using miRNeasy mini kit (Qiagen) according to the manufacturer\'s instructions. One microgram of total RNA was reverse-transcribed into cDNA, followed by PCR using primer sets corresponding to different *KIAA1549-BRAF* fusion genes and the *PBGD* and *B2M* reference genes (Table [2](#T2){ref-type="table"}). PCR products were analyzed on a 2% agarose gel. Pilocytic astrocytoma tissue containing the *KIAA1549*-*BRAF* fusions was used as a positive control. Additionally, tonsil tissue known to lack the *KIAA1549*-*BRAF* fusion genes was used as a negative control.

TSC1/TSC2 mutation and LOH analysis of SEGAs {#s4_5}
--------------------------------------------

In 3 cases (fresh frozen samples), targeted MPS was performed using a HaloPlex custom capture array as described previously \[[@R46]\]. In the other 31 cases (24 FFPE and 7 fresh frozen samples), targeted MPS was performed using a customized gene bait set (Agilent platform) designed in the Kwiatkowski lab that covers the entire *TSC1* and *TSC2* genes including 10 kb upstream and downstream and all coding exons and introns. This bait set also covered all coding exons and adjacent introns of *BRAF*. MPS was performed according to the following methods. Briefly, DNA was subjected to fragmentation using Covaris sonication to an average size of 250bp. The fragmented DNA was purified using Agencourt AMPure XP beads and ligated to the dual indexed adaptors for Illumina sequencing. A MiSeq run was performed to quantify each library. Libraries were then pooled in equal mass and captured using the custom baitset using Agilent SureSelect hybrid capture kit. The captured libraries were then sequenced on the either the HiSeq2500 or the HiSeq 3000 instrument.

The sequencing output was de-convoluted into individual sample reads and sorted using Picard tools \[[@R47]\]. Reads were aligned to the reference sequence hg19 from the Human Genome Reference Consortium using bwa \[[@R42], [@R48]--[@R50]\], and duplicate reads were identified and marked using the Picard tools. The alignments were further refined using the GATK tool for localized realignment around indel sites and recalibration of the quality scores was also performed using GATK tools \[[@R42], [@R49], [@R51]\]. Mutation analysis for single nucleotide variants (SNV) was performed using MuTect v1.1.4 and annotated by Variant Effect Predictor (VEP) \[[@R52], [@R53]\]. Insertions and deletions were called using Indel Locator and SomaticIndelDetector tool \[[@R42], [@R54]\]. MuTect was run in paired mode using a CEPH sample as a normal since normal DNA samples were not available, and a germline variant filter was then applied. Variants were filtered against the 6,500 exome release of the Exome Sequencing Project (ESP) database ExAC (exclude variants seen in more than 3 normal subjects; <http://exac.broadinstitute.org>), 1000G and GnomAD \[[@R55], [@R56]\]. Variants represented at \>1% in either the African-American or European-American subsets of these reference databases and not in COSMIC \> 2x were considered to be germline. Variants found in *BRAF* were analysed using cBio (<http://www.cbioportal.org>) and were further assessed for functionality using 3 different in silico prediction tools: PROVEAN (<http://provean.jcvi.org>), SIFT (<http://sift.jcvi.org>) and MutationAccessor (<http://mutationassessor.org>) \[[@R57]--[@R61]\].

A second approach was used in parallel to analyze the sequence data, with capture of read calls at all positions using SAMtools Pileup, followed by custom processing in Python and Matlab to determine base call frequency at each position in each read orientation. These data were then filtered to eliminate variant calls observed in only a single read orientation, or seen in multiple samples to exclude artifacts derived from the sequencing process. All variants observed at a frequency of \>1% were directly reviewed using the Integrative Genomics Viewer, to identify bona fide variant calls and exclude sequencing or alignment artifacts \[[@R21], [@R23], [@R26]\]. Potential pathogenic variants seen at frequency \> 1% were also examined in the GnomAD database and the TSC LOVD database.

A minimal median read depth of 20x coverage for the coding exons of *TSC1* and *TSC2* was required for the samples reported here. The median read depth for coding exons of *TSC1* and *TSC2* was a median of 107 (range 20 -- 1120) among the 31 samples.

LOH was assessed using two allele frequencies: 1) at the site of mutation, using Unix grep to precisely quantify mutant vs. wild-type reads for indel mutations; and 2) at all SNPs identified in the *TSC1* and *TSC2* genes that had a population allele frequency of \> 0.05% in the GnomAD database. If either the mutant allele frequency for the mutation was \> 55%, or the median SNP minor allele frequency for *TSC1*/*TSC2* was \< 40%, this was considered evidence of CN-LOH. LOH was assessed only in the tumor samples; normal brain tissue adjacent to the tumor, was not available.

**Author contributions**

EA and AM conceived the study and participated in its design and coordination together with DK. FJ, WS, WD, RC, IB, WP, TS, MF, KK, SJ, JJ, AMB, FG, FS, JP, AM and EA contributed to the collection and selection of tissue samples and/or clinical data. KG, MN and DK performed the DNA analyses including MPS. AB, KG conducted and analyzed most of the experiments supported by RR, JA and DK. AB, KG, JM, AM, EA and DK wrote the paper. All authors read and approved the final manuscript.

The authors thank all supporters of the TSC brain bank (Laboratory of Molecular and Cellular Neurobiology, International Institute of Molecular and Cell Biology, Warsaw, Poland: J. Jaworski, A Tempes; The Service d' Anatomie Pathologique, CHI de Creteil and Inserm U676, Hospital Robert Debre, Paris, France: H. Adle-Biassette; Department of Pediatrics, Institute of Neurology, Department of Neurosurgery, Medical University Vienna, Austria: T. Czech, J. Hainfellner; Department of Neuropathology, John Radcliffe Hospital, Oxford, UK: C. Kennard; Department of Anatomic Pathology Sciences, Università Sapienza, Rome, Italy: M. Antonelli, F. Giangaspero; Insitute of Neuropathology, Westfälische Wilhelms -- Universität Münster, Münster, Germany; Laboratory of Neuropathology, Department of Neurology, Hospital de Santa Maria (CHLN), Lisbon, Portugal; Department of Human Pathology and Oncology, University of Florence and Division of Neurosurgery, 'Anna Meyer' Pediatric Hospital, Florence, Italy).

**CONFLICTS OF INTEREST**

None of the authors has any conflict of interest to disclose. We confirm that we have read the Journal\'s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

**FUNDING**

This work was supported by KIKA (Stichting Kinderen Kankervrij; AB, EA), Stichting AMC Foundation and Stichting Michelle (EA); the Austrian Science Fund (FWF, no. J3499; AM); the European Union 7th framework program: acronym EPISTOP (grant agreement no. 602391; FJ, TS, SJ, JJ, MF, AM, EA, DK); the Polish Ministerial funds for science (years 2014-2018) for the implementation of international co-financed project (KK, SJ).

AKT

:   protein kinase B

AMLs

:   angiomyolipomas

*BRAF^V600E^*

:   *BRAF* V600E mutation

CN-LOH

:   copy neutral loss of heterozygosity

DIG

:   desmoplastic infantile gangliogliomas

DNET

:   dysembyoplastic neuroepithelial tumor

ESP

:   the Exome Sequencing Project

GFAP

:   glial fibrillary acidic protein

GG

:   ganglioglioma

HE

:   hematoxylin-eosin

HLA

:   human leukocyte antigen

LAM

:   lymphangioleiomyomatosis

LOH

:   loss of heterozygosity

MAF

:   mutant allele frequency

MAP2

:   microtubule-associated protein

MAPK/ERK

:   mitogen-activated protein kinase/extracellular signal-regulated kinase

MPS

:   massively parallel sequencing

mTORC1

:   mammalian TOR Complex 1

NMI

:   no mutation identified

PA

:   pilocytic astrocytoma

pS6

:   phospho-S6 ribosomal protein

PXA

:   pleomorphic xanthoastrocytoma

SEGAs

:   subependymal giant cell astrocytomas

SEN

:   subependymal nodules

SNPs

:   single nucleotide polymorphisms

SNV

:   single nucleotide variants

TSC

:   tuberous sclerosis complex

VEP

:   Variant Effect Predictor

WHO

:   world health organization

[^1]: These authors share the senior authorship
